argenex SE $ARGX Shares Acquired by Bessemer Group Inc.

Bessemer Group Inc. lifted its position in shares of argenex SE (NASDAQ:ARGX) by 97,614.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 62,537 shares of the company’s stock after buying an additional 62,473 shares during the period. Bessemer Group Inc. owned approximately 0.10% of argenex worth $52,590,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in ARGX. Abound Wealth Management boosted its position in argenex by 3,200.0% during the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after purchasing an additional 32 shares during the period. Sound Income Strategies LLC purchased a new stake in argenex during the 4th quarter worth $28,000. Ameriflex Group Inc. purchased a new stake in argenex during the 3rd quarter worth $32,000. Sunbelt Securities Inc. purchased a new stake in argenex during the 3rd quarter worth $36,000. Finally, Aventura Private Wealth LLC purchased a new stake in argenex during the 4th quarter worth $38,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Price Performance

NASDAQ:ARGX opened at $799.32 on Friday. The firm has a 50-day moving average of $760.29 and a two-hundred day moving average of $816.75. The stock has a market cap of $49.71 billion, a P/E ratio of 35.59, a PEG ratio of 1.31 and a beta of 0.46. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. The company had revenue of $1.31 billion during the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. As a group, equities analysts expect that argenex SE will post 25.08 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on ARGX shares. Citizens Jmp upped their price target on shares of argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a research report on Friday, February 27th. Guggenheim upped their price target on shares of argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Zacks Research raised shares of argenex from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. HC Wainwright upped their price target on shares of argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Finally, Deutsche Bank Aktiengesellschaft raised shares of argenex from a “hold” rating to a “buy” rating in a research report on Tuesday, March 10th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,017.78.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.